Blackstone enlists a murderers' row of advisors, including ex-Sanofi CEO Olivier Brandicourt, to steer life sciences biz
Among the biggest institutional investors in the current biotech craze, Blackstone has been unafraid to throw its weight around with a dedicated life sciences arm placing some hefty bets. Now, hoping to get a leg up in therapeutics and beyond, the firm is drafting four executives with lengthy résumés into the fight.
Blackstone Life Sciences has fleshed out its senior advisory team with the appointments of ex-Sanofi CEO and director Olivier Brandicourt, NPS Pharma veteran Francois Nader, former GE Healthcare and Medtronic CEO Omar Ishrak, and former Genomic Health CEO Kim Popovits, the investment giant said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.